Recent update on biological activities and pharmacological actions of liraglutide by Tiwari, J et al.
EXCLI Journal 2017;16:742-747 – ISSN 1611-2156 
Received: April 01, 2017, accepted: May 03, 2017, published: May 17, 2017 
 
 
742 
Letter to the editor: 
RECENT UPDATE ON BIOLOGICAL ACTIVITIES AND  
PHARMACOLOGICAL ACTIONS OF LIRAGLUTIDE 
 
Juhi Tiwari1, Gaurav Gupta1,2*, Rajiv Dahiya3, Kavita Pabreja2, Rakesh Kumar Sharma4, 
Anurag Mishra4, Kamal Dua5,6,7 
 
1 School of Pharmacy, Jaipur National University, Jagatpura 302017, Jaipur, India 
2 School of Medicine and Public Health, University of Newcastle, Newcastle, NSW 2308, 
Australia 
3 Laboratory of Peptide Research and Development, School of Pharmacy, Faculty of Medi-
cal Sciences, The University of the West Indies, St. Augustine, Trinidad & Tobago, West 
Indies 
4 School of Pharmacy, Suresh Gyan Vihar University, Jagatpura 302017, Jaipur, India 
5 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, 
Sydney, NSW 2007, Australia 
6 School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle,  
NSW 2308, Australia 
7 School of Pharmaceutical Sciences, Shoolini University, Solan, Himachal Pradesh, 
173229, India 
 
* corresponding author: Dr. Gaurav Gupta, School of Pharmacy, Jaipur National  
University, Jagatpura 302017, Jaipur, India, E-mail: gauravpharma25@gmail.com;  
Contact number: +91 7014790412 
 
 
http://dx.doi.org/10.17179/excli2017-323 
 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License  
(http://creativecommons.org/licenses/by/4.0/). 
 
Dear Editor,  
Liraglutide (LG), an analog of human glucagon-like peptide 1 (GLP-1), has been permitted 
for type 2 diabetes therapy. LG triggers the GLP-1 receptor, leading to release of insulin in the 
presence of high glucose concentrations, it declines secretion of glucagon in a glucose-depend-
ent manner and directly applying to the β cells of pancreas to help its proliferation and differ-
entiation (Dharmalingam et al., 2011; Drucker et al., 2010). The mechanism of lowering blood 
glucose also includes a delay in gastric emptying. LG is approved by the European Medicines 
Agency (EMA) on July 3, 2009, and by the U.S. Food and Drug Administration (FDA) on 
January 25, 2010, for the treatment of type 2 diabetes mellitus (T2DM) (Ye et al., 2017). A 
number of studies suggest that LG, GLP-1 has additional benefits (Zhang et al., 2017). Here we 
have reviewed various pharmacological actions of LG (Table 1). 
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Table 1: Recent update on biological activities and pharmacological actions of liraglutide 
Key Findings References 
By targeting insulin receptor substrate 1 on the diabetic rat pancreas and insu-
lin 1 cells, LG exhibits anti-apoptotic effect by decreased miR-139-5p expres-
sion. 
Li et al., 2017 
By declining the phosphorylation of tau, LG alleviates Alzheimer disease-like 
cognitive impairment. 
Qi et al., 2017 
In T2DM patients with non-alcoholic fatty liver disease, compare to metformin 
and gliclazide, LG showed a better recovery in hepatic function, decreases in 
integration host factor content and level of HbA1c, and reduction in weight. 
Feng et al., 2017 
LG in a one dose can acutely inhibit the ketogenesis. Garg et al., 2017 
Therapy with a combination of Insulin Degludec (IDeg) and LG (IDegLira) al-
lows more patients with type 2 diabetes to sustain the level of blood glucose 
within target ranges all over the day compared to IDeg or LG alone. 
King et al., 2017 
LG can protect cardiomyocytes against reperfusion injury through modulation 
of intracellular calcium homeostasis. 
Hu et al., 2017 
LG and sitagliptin showed an auspicious approach to moderate the progres-
sion of Parkinson’s disease by their anti-inflammatory, anti-apoptotic neu-
rotrophic and neurogenic mechanistic activities. 
Badawi et al., 
2017 
Treatment of LG 3.0 mg may deliver benefit for health in terms of reduced risk 
of diabetes in persons with obesity and prediabetes. 
le Roux et al., 
2017 
LG 1.8 mg is likely to be cost-effective compared with lixisenatide 20 μg in T2D 
patients who have not attained glycemic control targets on metformin mono-
therapy. 
Mezquita-Raya et 
al., 2017 
LG therapy may help patients in primary care by postponing the need for fur-
ther treatment strengthening. 
Martinez et al., 
2017 
LG accompanying with metformin induces a significantly clinical enhancement 
in β-cell function in obese and patients with cardiovascular diseases with newly 
diagnosed well-controlled T2DM and coronary artery diseases.  
Anholm et al., 
2017 
LG showed daytime variation in the effect on blood pressure without upsetting 
the blood pressure inconsistency or night-time blood pressure dropping. 
Kumarathurai et 
al., 2017a 
Treatment of T2DM patients with LG 1.8 mg is expected to be measured highly 
cost-effective compared with lixisenatide 20 µg in the UK setting. 
Hunt et al., 2017 
LG causes a considerable and quick EAT reduction. Liraglutide cardiometa-
bolic effects may be EAT-mediated. 
Iacobellis et al., 
2017 
LG treatment showed anti-inflammatory, reflected in decreases in TNF-α and 
MR-proADM, whereas a decrease in MR-proANP may signify a clinically rele-
vant regarding cardiac failure. 
von Scholten et 
al., 2017 
LG 3.0 mg treatment showed safe and effective addition to the pharmacologic 
effect for chronic weight management in the overall population. 
Manigault and 
Thurston, 2016 
Through an effect on mTOR pathway, LG protected diabetes-dependent hippo-
campal neurodegeneration. 
Palleria et al., 
2017 
In obese patients with T2D, LG expressively enhanced glycemic control and 
decreased the body weight without failing quality of life. 
Ishii et al., 2017 
LG has valuable effects in a mouse model of moderate uremia by decreasing 
atherosclerosis and inflammation of kidney. 
Bisgaard et al., 
2016 
LG defends in contrast to IR injury of the hepatic tissue through anti-inflamma-
tory and antioxidant activities along with inhibition of apoptosis. 
Abdelsameea et 
al., 2017 
IDegLira provided superior glycemic control versus unchanged GLP-1RA and 
represents an efficacious intensification approach in patients inadequately con-
trolled on GLP-1Ras. 
Jennings et al., 
2016 
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Table 1 (cont.): Recent update on biological activities and pharmacological actions of liraglutide 
Key Findings References 
LG treatment progresses myocardial recovery and infarct size after ST-seg-
ment-elevation myocardial infarction, possibly by reducing reperfusion injury, 
making it a promising treatment for evaluation in larger trials 
Chen et al., 2016 
LG treatment as add-on to insulin improved HR and did not progress other car-
diovascular risk factors after 6 months of treatment in patients with chronic 
T1D. 
Dejgaard et al., 
2017 
In insulin-treated patients with T2D, LG treatment may reduce visceral adipos-
ity in parallel with the reduction of hepatic fat accumulation, albuminuria and 
micro-inflammation and progress quality of life associated with diabetes care. 
Bouchi et al., 
2017 
LG treatment might improve the therapeutic efficacy of mesenchymal stem 
cells in the treatment of T1D. 
Li et al., 2016a 
LG treatment decreased ostomy wet weight production in end-jejunostomy pa-
tients with SBS-IF and improved their intestinal wet weight and energy absorp-
tion. 
Hvistendahl et al., 
2016 
LG treatment delays onset of EAE in Lewis rats and is associated with im-
proved protective capacity against oxidative stress. 
Bouchi et al., 
2017 
In failing post-ischemic T2D patients, LG therapy improves heart function and 
functional capacity. 
Arturi et al., 2016 
LG improved heart rate and decreased heart rate variability despite weight loss 
and enhancement of metabolic parameters in overweight patients with CAD 
and newly diagnosed T2D. The rise in nocturnal heart rate in combination with 
a reduction in parasympathetic activity parameters proposes that LG may af-
fect sympathovagal balance. 
Kumarathurai et 
al., 2017b 
Treatment of LG re-establishes angiogenesis in PA-impaired HUVECs via up-
regulation of GTPCH1 and eNOS in a PI3K/Akt-Foxo1-dependent mechanism. 
Ke et al., 2016 
Pre-treatment with LG reduced lipopolysaccharide-induced acute lung injury by 
preventing the NLRP3 inflammasome pathway. 
Zhou et al., 2016 
LG has pleiotropic effects on renal risk factors. Zobel et al., 2017 
Due to its safety and hypoglycemic efficacy, liraglutide is an excellent choice 
for DM treatment in combination with other drugs. Its effects on the reduction of 
weight and other cardiovascular risk factors, make it an optimal treatment, es-
pecially in overweight or obese patients. 
Calvo Gomez et 
al., 2016 
Six months of treatment with liraglutide 1.2 mg/d significantly reduced LFC in 
patients with inadequately controlled type 2 diabetes and this effect was mainly 
driven by body weight reduction. 
Petit et al., 2017 
In Indian T2D patients, treatment of LG resulted in a significant and continued 
decrease in HbA1c and body weight over a year and it was associated with 
baseline HbA1c and weight, respectively. 
Kaur et al., 2016 
LG is safe and well tolerated for non-diabetic individuals with mood disorders 
as well as shows beneficial effects on objective measures of cognitive function. 
Mansur et al., 
2017 
LG might be moderate in the conformation of the gut microbiota, leads to a 
more lean-related profile that was consistent with its weight-losing effect. 
Wang et al., 
2016a 
Through modification of AMPK/mTOR signaling, LG weakens osteoblastic dif-
ferentiation of MC3T3 E1 cells. 
Hu et al., 2016 
LG may have a beneficial role in pulmonary vascular remodeling, because of 
its defensive and therapeutic effects on monocrotaline-induced pulmonary arte-
rial hypertension, through the eNOS/sGC/PKG and Rho kinase pathways.  
Lee et al., 2016 
LG may hinder in the metabolism of energy because analysis of different times 
of administrations, concentrations, and level of brain development leads to dif-
ferent outcomes. 
Pra et al., 2016 
The useful effects of LG on pancreatic islets seem to be linked to its anti-in-
flammatory and anti-oxidative properties. These conclusions showed that LG 
could be used to progress graft survival. 
Langlois et al., 
2016 
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Table 1 (cont.): Recent update on biological activities and pharmacological actions of liraglutide 
Key Findings References 
LG in addition to insulin therapy declines HbA1c levels, total insulin dose, and 
body weight in a population that was usually demonstrative of subjects with 
T1D, together with increased rates of symptomatic hypoglycemia and hypergly-
cemia with ketosis, thereby limiting clinical use in this group. 
Mathieu et al., 
2016 
LG and Linagliptin through the initiation of the ERK/NF-κB/pathway, prevent 
glucose- and Ang II-induced collagen formation in cardiac fibroblasts. 
Wang et al., 
2016b 
In T2D patients, LG therapy for 180 days is associated with a perfection in di-
astolic function. 
Saponaro et al., 
2016 
LG progresses endothelial function, weakens endothelial inflammatory signals, 
as well as converses leptin resistance. 
Li et al., 2016b 
In T2D patients, LG may be beneficial for treating insulin allergy and anti-insu-
lin antibodies. 
Htike et al., 2016 
Without modifying the level of plasma insulin, LG effectively enhanced glyce-
mic instability due to insulin antibodies. 
Kato et al., 2016 
Early use of LG may decrease metabolic insulin resistance and stop cardiovas-
cular problems of diabetes. It exhibits their beneficial glycemic effect by im-
proving microvascular insulin sensitivity and muscle capillary density during in-
sulin resistance development. 
Chai et al., 2016 
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